John (Jack)_Kellie

John (Jack) Kellie


Dr. John Kellie is currently a Scientific Leader and GSK Fellow in the Bioanalysis, Immunogenicity, and Biomarkers group at GlaxoSmithKline. John received his B.S. in Biochemistry from Indiana University and his Ph.D. in Chemistry from Northwestern studying under Dr. Neil Kelleher. He was a Post-Doctoral Scientist at Eli Lilly and Company where he developed methods for intact protein quantitation of a Parkinson’s Disease biomarker from human brain tissue. At GSK, John utilizes mass spectrometry for development of novel bioanalytical methods for biotherapeutic & protein quantitation from pre-clinical and clinical samples, with a focus on intact protein and large mass quantitation for pharmacokinetics, catabolism, biotransformation, and product quality attribute support.